JP2019518003A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518003A5 JP2019518003A5 JP2018555141A JP2018555141A JP2019518003A5 JP 2019518003 A5 JP2019518003 A5 JP 2019518003A5 JP 2018555141 A JP2018555141 A JP 2018555141A JP 2018555141 A JP2018555141 A JP 2018555141A JP 2019518003 A5 JP2019518003 A5 JP 2019518003A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- peptide
- vectors
- vector
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 20
- 108090000174 Interleukin-10 Proteins 0.000 claims 17
- 108010017550 Interleukin-10 Receptors Proteins 0.000 claims 16
- 102000003814 Interleukin-10 Human genes 0.000 claims 13
- 229940076144 interleukin-10 Drugs 0.000 claims 13
- 239000013598 vector Substances 0.000 claims 13
- 102000004551 Interleukin-10 Receptors Human genes 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 108091026890 Coding region Proteins 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 5
- 239000013603 viral vector Substances 0.000 claims 5
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 238000007913 intrathecal administration Methods 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 235000004400 serine Nutrition 0.000 claims 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Chemical group 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 210000004507 artificial chromosome Anatomy 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Chemical group SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 210000000497 foam cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 210000000274 microglia Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000003003 monocyte-macrophage precursor cell Anatomy 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 210000004248 oligodendroglia Anatomy 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 235000008521 threonine Nutrition 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022124716A JP2022169585A (ja) | 2016-04-22 | 2022-08-04 | インターロイキン１０の抗炎症効果を亢進するための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326082P | 2016-04-22 | 2016-04-22 | |
| US62/326,082 | 2016-04-22 | ||
| PCT/US2017/028755 WO2017184933A1 (en) | 2016-04-22 | 2017-04-21 | Methods and compositions to enhance the anti-inflammatory effects of interleukin 10 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022124716A Division JP2022169585A (ja) | 2016-04-22 | 2022-08-04 | インターロイキン１０の抗炎症効果を亢進するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019518003A JP2019518003A (ja) | 2019-06-27 |
| JP2019518003A5 true JP2019518003A5 (enExample) | 2020-05-14 |
| JP7163189B2 JP7163189B2 (ja) | 2022-10-31 |
Family
ID=60116475
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555141A Active JP7163189B2 (ja) | 2016-04-22 | 2017-04-21 | インターロイキン１０の抗炎症効果を亢進するための方法および組成物 |
| JP2022124716A Pending JP2022169585A (ja) | 2016-04-22 | 2022-08-04 | インターロイキン１０の抗炎症効果を亢進するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022124716A Pending JP2022169585A (ja) | 2016-04-22 | 2022-08-04 | インターロイキン１０の抗炎症効果を亢進するための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190112354A1 (enExample) |
| EP (1) | EP3445849B1 (enExample) |
| JP (2) | JP7163189B2 (enExample) |
| KR (1) | KR102430455B1 (enExample) |
| CN (1) | CN109477085B (enExample) |
| AU (1) | AU2017252327B2 (enExample) |
| CA (1) | CA3019846A1 (enExample) |
| DK (1) | DK3445849T3 (enExample) |
| IL (1) | IL262195B2 (enExample) |
| RU (1) | RU2731160C2 (enExample) |
| WO (1) | WO2017184933A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57974B1 (sr) | 2013-07-18 | 2019-01-31 | Xalud Therapeutics Inc | Sastavi za lečenje inflamatornog oboljenja zglobova |
| CN111971026A (zh) | 2018-05-24 | 2020-11-20 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
| EP3803866A4 (en) | 2018-05-24 | 2022-03-16 | Nureva Inc. | METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS |
| BR112020023982A2 (pt) | 2018-05-24 | 2021-02-23 | Celanese Eva Performance Polymers Llc | dispositivo implantável para liberação prolongada de um composto de fármaco macromolecular |
| WO2021093790A1 (en) * | 2019-11-11 | 2021-05-20 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric genes |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| KR102466921B1 (ko) * | 2021-06-29 | 2022-11-14 | 주식회사 오에이티씨 | 인터루킨-4를 암호화하는 유전자를 포함하는 신경병증성 통증의 예방 또는 치료용 약학적 조성물 |
| US20250051412A1 (en) * | 2021-12-16 | 2025-02-13 | Xalud Therapeutics, Inc. | Dosing regimen for il-10 encoding expression construct |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716804A (en) * | 1995-04-19 | 1998-02-10 | Schering Corporation | Mammalian interleukin-10 (IL-10) super-activating receptors; and variants |
| US7261882B2 (en) * | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| EP1891103B1 (en) * | 2005-05-31 | 2009-12-23 | The Regents of the University of Colorado | Mutant il-10 |
| TWI688395B (zh) * | 2010-03-23 | 2020-03-21 | 英翠克頌公司 | 條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途 |
| US9315825B2 (en) * | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| EP2800554A4 (en) * | 2012-01-06 | 2015-06-03 | Univ Colorado Regents | METHOD FOR TREATING MULTIPLE SCLEROSIS AND OTHER DEMYELINISING DISEASES |
| RS57974B1 (sr) * | 2013-07-18 | 2019-01-31 | Xalud Therapeutics Inc | Sastavi za lečenje inflamatornog oboljenja zglobova |
-
2017
- 2017-04-21 DK DK17786683.7T patent/DK3445849T3/da active
- 2017-04-21 JP JP2018555141A patent/JP7163189B2/ja active Active
- 2017-04-21 KR KR1020187033641A patent/KR102430455B1/ko active Active
- 2017-04-21 US US16/094,006 patent/US20190112354A1/en not_active Abandoned
- 2017-04-21 RU RU2018140988A patent/RU2731160C2/ru active
- 2017-04-21 WO PCT/US2017/028755 patent/WO2017184933A1/en not_active Ceased
- 2017-04-21 CN CN201780025135.5A patent/CN109477085B/zh active Active
- 2017-04-21 AU AU2017252327A patent/AU2017252327B2/en active Active
- 2017-04-21 CA CA3019846A patent/CA3019846A1/en active Pending
- 2017-04-21 IL IL262195A patent/IL262195B2/en unknown
- 2017-04-21 EP EP17786683.7A patent/EP3445849B1/en active Active
-
2022
- 2022-08-04 JP JP2022124716A patent/JP2022169585A/ja active Pending
-
2024
- 2024-04-29 US US18/648,678 patent/US20240352089A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518003A5 (enExample) | ||
| RU2018140988A (ru) | Способы и композиции для усиления противовоспалительных эффектов интерлейкина 10 | |
| JP7731579B2 (ja) | 細胞並びにその使用方法及び製造方法 | |
| Cheroutre et al. | CD4 CTL: living up to the challenge | |
| Zhang et al. | GDF15 regulates Malat-1 circular RNA and inactivates NFκB signaling leading to immune tolerogenic DCs for preventing alloimmune rejection in heart transplantation | |
| Xiao et al. | CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy | |
| JP6561372B2 (ja) | 免疫機能制御因子を発現する免疫担当細胞及び発現ベクター | |
| Li et al. | Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis | |
| ES2684493T3 (es) | Un polipéptido SAP para uso en el tratamiento de trastornos autoinmunitarios y enfermedad del injerto contra el huésped | |
| US20220073585A1 (en) | Chimeric antigen receptor memory-like (carml) nk cells and methods of making and using same | |
| RU2014132426A (ru) | Частичные конструкты мнс и способы их применения | |
| ES2908553T3 (es) | Métodos para expandir una población de macrófagos alveolares en un cultivo de larga duración | |
| Li et al. | Regulatory rebound in IL-12–treated tumors is driven by uncommitted peripheral regulatory T cells | |
| JP2014523252A5 (enExample) | ||
| WO2022012531A1 (zh) | 一种经修饰的免疫细胞的制备方法 | |
| CN101948544B (zh) | FAT10基因siRNA重组模拟病毒及其制备方法和应用 | |
| JP2023040034A (ja) | 耐性を誘導するための操作された細胞 | |
| Horn et al. | Gene therapy in the transplantation of allogeneic organs and stem cells | |
| WO2025101276A1 (en) | Compositions and methods for making and using immune cells | |
| Yang et al. | Downregulating immunogenicity of Schwann cells via inhibiting a potential target of class II transactivator (CIITA) gene | |
| Maharaj et al. | Can juvenile idiopathic arthritis be cured? | |
| WO2015169994A1 (es) | Composición capaz de modular la actividad de sidt1 para el tratamiento de enfermedades infecciosas inflamatorias o autoinmunes mediadas por ifn | |
| Zhang | Leading to Immune Tolerogenic DCs for Preventing Alloimmune Rejection | |
| WO2008112218A2 (en) | Li-rnai involved li suppression in cancer immunotherapy | |
| WO2025096975A1 (en) | Compositions and methods of enhancing immune cell therapies by runx2 modulation |